Terns Pharmaceuticals Inc... (TERN)
NASDAQ: TERN
· Real-Time Price · USD
7.41
0.11 (1.51%)
At close: Sep 17, 2025, 3:59 PM
7.63
3.04%
After-hours: Sep 17, 2025, 07:51 PM EDT
1.51% (1D)
| Bid | 7.12 |
| Market Cap | 648.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -91.75M |
| EPS (ttm) | -1.03 |
| PE Ratio (ttm) | -7.19 |
| Forward PE | -5.7 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.75 |
| Volume | 794,995 |
| Avg. Volume (20D) | 1,082,607 |
| Open | 7.59 |
| Previous Close | 7.30 |
| Day's Range | 7.37 - 7.75 |
| 52-Week Range | 1.86 - 10.70 |
| Beta | -0.05 |
| Ex-Dividend Date | n/a |
About TERN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TERN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TERN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-5.64%
TERN stock has given up its prior gain. Terns Phar...
Unlock content with
Pro Subscription
2 months ago
-5.64%
Terns Pharmaceuticals shares are trading higher after the company announced it will highlight data from the completed Phase 1 study of TERN-601 at the American Diabetes Association 85th Scientific Sessions. Also, the company completed enrollment for the Phase 2 FALCON trial.
1 month ago · fool.com
Terns (TERN) Q2 Net Loss Narrows 16%Terns (TERN) Q2 Net Loss Narrows 16%
2 months ago · seekingalpha.com
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology CatalystsTerns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-c...